The results of the recently completed FOURIER trial suggest that we have taken a huge step forward in the pharmacological therapy atherosclerotic cardiovascular disease (ASCVD). On February 2, 2017 the biotechnological company Amgen announced that the FOURIER trial evaluating whether the drug evolocumab (Repatha) reduces the risk of cardiovascular events in patients with clinically evident ASCVD … Read more
Knowing the role of VLDL (very low-density lipoprotein) and chylomicrons is a key factor in understanding how lipids (fats) and lipoproteins are involved in atherosclerotic cardiovascular disease (ASCVD). In the current era of adiposity and metabolic disease, VLDL has gained a bigger role than before and may help explain many of the disorders associated with the obesity epidemic such … Read more
Niacin (nicotinic acid), also known as vitamin B3, is one of eight known B vitamins. It has been used for decades to lower cholesterol and reduce cardiovascular risk. However, today its use is somewhat debated. Meat and fish are the richest sources of nicotinic acid followed by fortified enriched grain, vegetables, and yeast. Tuna, salmon, chicken, turkey, … Read more
Elevated LDL-cholesterol (LDL-C) is common among people who adopt a low-carb, high-fat (LCHF) lifestyle. That’s why many physicians and nutritionists remain doubtful when it comes to LCHF, despite overwhelming evidence that such a dietary approach improves several other lipid parameters, usually leads to weight loss and positively affects glucose metabolism. Several studies have shown that LDL-C constitutes a major risk factor for the … Read more
By now, all of us should know that we are in the throes of an obesity epidemic. Worldwide, over 500 million people are believed to be affected (1). Obesity in children and adolescents is on the rise and so is type 2 diabetes. And, according to the media and the experts, this will have horrible consequences that ultimately will … Read more